Company to Host Investor Conference Call
NuPathe will host a conference call tomorrow, January 18, 2013, at 8:30 a.m. EST to discuss the FDA approval of Zecuity. A question and answer session will follow NuPathe's remarks. To participate on the live call, please dial 888-329-8862 (domestic) or +1-719-325-2420 (international), and provide the participant passcode 9170164 five to ten minutes before the start of the call. A live audio webcast of the call will be available via the Investor Relations page of the NuPathe website, www.nupathe.com. Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time.
A replay of the webcast will also be archived on the Company's website for 90 days following the call. A replay of the call will be available for 90 days within a few hours after the call ends. Investors may listen to the replay of the call by dialing 888-203-1112 (domestic) or +1-719-457-0820 (international), with the passcode 9170164.
About Migraine and Migraine-Related Nausea (MRN)
Migraine is a debilitating neurological disease afflicting a large underserved patient population. Migraine is characterized by headache pain accompanied by associated neurological and GI symptoms including nausea, vomiting, photophobia, and phonophobia.(1,2) In the U.S., 31 million adults, with approximately three times as many women as men,(3) suffer from migraine.(3,4,5) Of the 16 million migraine patients who are diagnosed and treated, approximately eight million experience migraine-related nausea (MRN) in at least half of their migraine attacks.(6) These frequent-MRN patients report significantly more migraine symptom burden and experience significantly more interference with work, social and family life.(6) Many migraine patients who experience MRN delay or avoid taking orally administered medications due to nausea or vomiting.(7)
NuPathe Inc. is a specialty pharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product, Zecuity (sumatriptan iontophoretic transdermal system), has been approved by the FDA for the acute treatment of migraine with or without aura in adults. Zecuity is expected to be available by prescription in the fourth quarter of 2013. In addition to Zecuity, NuPathe has two proprietary product candidates based on its LAD, or Long-Acting Delivery, biodegradable implant technology that allows delivery of therapeutic levels of medication over a period of months with a single dose. NP201, for the continuous symptomatic treatment of Parkinson's disease, utilizes a leading FDA-approved dopamine agonist, ropinirole, and is being developed to provide up to two months of continuous delivery. NP202, for the long-term treatment of schizophrenia and bipolar disorder, is being developed to address the long-standing problem of patient noncompliance by providing three months of continuous delivery of risperidone, an atypical antipsychotic. NuPathe is actively seeking partnerships to maximize the commercial potential for Zecuity and its other product candidates in the U.S. and territories throughout the world.
Most Popular Stories
- Maui Visitor Killed in Shark Attack
- Brazil Braces for Street Protests at World Cup
- Boehner Hires Immigration Reform Expert
- Donors Abandon GOP Over Gun Stance
- Sprint Not Moving Headquarters to California
- Dennis Kozlowski, ex-Tyco CEO, to Be Paroled
- Healthcare.gov Update Gets Mixed Reviews
- Mexico Economy Secretary to Attend WTO Meeting
- Appeals Court Sides With Employers on Arbitration
- Miley Cyrus to Rihanna Lyrics: Top Yahoo Searches for 2013